Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease

Advanced glycation end products (AGEs) are aging products. In chronic kidney disease (CKD), AGEs accumulate due to the increased production, reduced excretion, and the imbalance between oxidant/antioxidant capacities. CKD is therefore a model of aging. The aim of this review is to summarize the present knowledge of AGEs in CKD onset and progression, also focusing on CKD-related disorders (cardiovascular diseases, sarcopenia, and nutritional imbalance) and CKD mortality. The role of AGEs as etiopathogenetic molecules, as well as potential markers of disease progression and/or therapeutic targets, will be discussed.

Automated summary

Advanced glycation end products (AGEs) are aging products that accumulate in chronic kidney disease (CKD) due to increased production, reduced excretion, and imbalance between oxidant/antioxidant capacities. This review aims to summarize the knowledge of AGEs in CKD onset and progression, focusing on related disorders and mortality. The role of AGEs as etiopathogenetic molecules and potential markers or therapeutic targets will be discussed.